Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 46.00
Change Today -1.00 / -2.13%
Volume 140.5K
XTLB On Other Exchanges
Symbol
Exchange
NASDAQ CM
Tel Aviv
As of 9:24 AM 04/19/15 All times are local (Market data is delayed by at least 15 minutes).

xtl biopharmaceuticals ltd (XTLB) Snapshot

Open
$47.00
Previous Close
$47.00
Day High
$46.40
Day Low
$44.50
52 Week High
04/24/14 - $67.00
52 Week Low
10/21/14 - $31.10
Market Cap
125.8M
Average Volume 10 Days
268.0K
EPS TTM
$-0.01
Shares Outstanding
273.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XTL BIOPHARMACEUTICALS LTD (XTLB)

Related News

No related news articles were found.

xtl biopharmaceuticals ltd (XTLB) Related Businessweek News

No Related Businessweek News Found

xtl biopharmaceuticals ltd (XTLB) Details

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs. The company’s lead drug candidate is hCDR1, a Phase II clinical trial product for the treatment of systemic lupus erythematosus related autoimmune process; and recombinant human erythropoietin (rHuEPO) for the treatment of multiple myeloma patients, as well as for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia. Its rHuEPO has also granted an orphan drug designation from the FDA for the treatment of multiple myeloma. The company is also developing SAM-101, a proprietary combination of antipsychotic drugs and a medicinal compound, which has completed Phase IIa clinical trials as a therapy for psychotic diseases with focus on schizophrenia. It has a licensing agreement with Yeda Research and Development Company for the development of hCDR1. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is based in Herzliya, Israel.

12 Employees
Last Reported Date: 04/2/14
Founded in 1993

xtl biopharmaceuticals ltd (XTLB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

xtl biopharmaceuticals ltd (XTLB) Key Developments

XTL Biopharmaceuticals Ltd., Special/Extraordinary Shareholders Meeting, Mar 25, 2015

XTL Biopharmaceuticals Ltd., Special/Extraordinary Shareholders Meeting, Mar 25, 2015., at 11:00 Israel Standard Time. Location: Law Offices of the Company's attorneys, Kantor & Co.. Agenda: To elect Mr. Oded Nagar and Mrs. Osnat Hillel Fein to hold office as external directors; to elect Mrs. Osnat Hillel Fein to hold office as external director of the company; and to approve the grant to Mr. Josh Levine of the CEO Compensation.

XTL Biopharmaceuticals Ltd. Announces Board Appointments

XTL Biopharmaceuticals Ltd. announced that the company's shareholders approved the appointment of two new members to the Board of Directors, Doron Turgeman and Shlomo Shalev. Turgeman is currently the Chief Executive Officer of B Communications (BCOM) and Internet Gold (IGLD). Shlomo Shalev most recently served as Chairman of the Board of Micronet.

XTL Biopharmaceuticals Ltd. Announces Board Appointments

XTL Biopharmaceuticals Ltd. announced that the Board of Directors has appointed two new members, Dr. Jonathan Schapiro and Dr. Dobroslav Melamed. Dr. Jonathan Schapiro, 54, is currently an Adjunct Clinical Assistant Professor in the Department of Medicine, Division of Infectious Diseases and Geographic Medicine at Stanford University School of Medicine and a Director of HIV/AIDS at the National Hemophilia Center at Sheba Medical Center in Tel Aviv, Israel. He has served as a committee member on the United States Food and Drug Administration Antiviral Drugs Advisory Committee and is a member of the World Health Organization Global HIV Drug Resistance Network Steering Group. Dr. Dobroslav Melamed, 37, is a biotech entrepreneur with over 10 years of experience in the life science industry. He has demonstrated success in taking drugs from the lab to the shelf by identifying target markets, planning regulatory strategy, raising capital, executing successful clinical trials and scaling up to commercial production. He is currently establishing two companies involved in the development of a treatment for Ebola and novel drug delivery.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XTLB:IT 46.00 -1.00

XTLB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for XTLB.
View Industry Companies
 

Industry Analysis

XTLB

Industry Average

Valuation XTLB Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XTL BIOPHARMACEUTICALS LTD, please visit www.xtlbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.